Cellular Biomedicine Group announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.
Upon the closing of the licensing and collaboration agreement, CBMG – a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases – will receive $40 million in an equity purchase from Novartis. Novartis will receive certain royalty-free intellectual property worldwide rights to certain CBMG CAR-T related technology. CBMG will receive a single-digit escalating percentage collaboration payment based on net product sales. CBMG will receive a mark-up from Novartis on the manufacturing cost. CBMG will take the lead in the manufacturing process, and Novartis will lead distribution, regulatory and commercialization efforts in China.
Headquartered in Silicon Valley, San Francisco Bay Area (USA), Cellular Biomedicine Group develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The company conducts immuno-oncology and stem cell clinical trials in China using products from its own integrated GMP laboratory. Its facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and US GMP standards. Shanghai CMBG facility includes a ‘Joint Laboratory of Cell Therapy’ with GE Healthcare and a ‘Joint Cell Therapy Technology Innovation and Application Center’ with Thermo Fisher Scientific.